The need for new antibacterial drugs to treat the increasing global prevalence of drug-
resistant bacterial infections has clearly attracted global attention, with a range of existing …

Antimicrobial resistance is one of the major problems in current practical medicine. The
spread of genes coding for resistance determinants among bacteria challenges the use of …

The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …

The antibacterial agents currently in clinical development are predominantly derivatives of
well-established antibiotic classes and were selected to address the class-specific …

As of January 2023, SARS-CoV-2 subvariants BQ. 1 (a BA. 5 subvariant) and XBB (a BA. 2
subvariant) have replaced previously dominant omicro n variants globally, including BA. 5 …

A major resistance mechanism in Gram-negative bacteria is the production of β-lactamase
enzymes. Originally recognized for their ability to hydrolyze penicillins, emergent β …

Despite major advances in the β-lactamase inhibitor field, certain enzymes remain refractory
to inhibition by agents recently introduced. Most important among these are the class B …

The β-lactams are the most widely used antibacterial agents worldwide. These antibiotics, a
group that includes the penicillins and cephalosporins, are covalent inhibitors that target …

Acinetobacter baumannii is a common cause of serious nosocomial infections. Although
community-acquired infections are observed, the vast majority occur in people with …

Infections caused by resistant bacteria are nowadays too common, and some pathogens
have even become resistant to multiple types of antibiotics, in which case few or even no …